Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a userÔÇÖs glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
Number of employees : 12 people.
|Implantable Visual Prosthetics||3.38||100%||-||-||-|
|USD in Million
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Gregg G. Williams ||9,890,810||
|Empery Asset Management LP ||3,300,000||
|The Vanguard Group, Inc. ||1,155,297||
|Versant Venture Management LLC ||561,612||
|BlackRock Fund Advisors ||399,886||
|Hudson Bay Capital Management LP ||380,404||
|Altium Capital Management LP ||373,867||
|Susquehanna Financial Group LLLP ||273,955||
|NewGen Asset Management Ltd. ||200,000||
|Sabby Capital LLC ||174,900||
Sector Medical Devices & Implants
Connections : Second Sight Medical Products, Inc.